Learn why people trust TAKHZYRO to help reduce their HAE attacks.
DENNIS: My doctor told me about TAKHZYRO, and my wife and I did some research. At the end of the day, I trusted my medical team and what they told me. After discussing the potential risks and the possibility of fewer HAE attacks, we decided it was the right treatment to take. And it's definitely made a big difference for me. I'm glad I listened.
KELLY: Seeing the clinical data and how effective TAKHZYRO was got my attention. It told me that this is a clinically proven treatment to help prevent HAE attacks, and that gave me the confidence to start.
JACK: For me, taking TAKHZYRO once every two weeks means it's not something I need to think about often. Plus, it's subcutaneous, which means it's injected under the skin, not in the vein. That feels manageable for me.
ANDREW: The actual injection takes about a minute, and then I'm free from thinking about my next dose for a few weeks.
SORAYA: I can inject myself, and it takes about a minute. It's an important thing I can do for myself to help reduce the frequency and severity of my HAE attacks.
NARRATOR: What is TAKHZYRO? TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age. Important safety information. TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
NARRATOR: Please see full Prescribing Information, including information for patients, at TAKHZYRO.com. Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.
